Pre-mixed blends are best reserved for the maintenance phase once both compounds are at stable target doses
Combine topical on the face with SubQ GHK-Cu injection for full-spectrum support
While its safety profile was consistently favorable, the largest Phase IIb trial failed to show statistical significance for weight loss, and commercial development was halted in 2007.[2] Despite this, interest in AOD-9604 has continued in the compounding pharmacy and integrative medicine space, particularly given its safety data, its lack of IGF-1 stimulation, and emerging research around joint health
Nature 586 , 567571 (2020)
Pass / Fail Criteria The basic criteria were: %BA close to 0.9% pH around 4.57 Sterility: no growth Endotoxin: 0.25 EU/mL Sampling Caveats The results matter, but they shouldnt be overstated
There is no published clinical data on the combination of AOD 9604 and semaglutide